Showing results (21-30 of 383) with videos related to
Sort By:
Pageof 39
Plos One|October 7, 2015
Concordance of Results from Randomized and Observational Analyses within the Same Study: A Re-Analysis of the Women's Health Initiative Limited-Access DatasetMark J Bolland, Andrew Grey, Greg D Gamble, et al.The Journal of Clinical Endocrinology and Metabolism|February 5, 2010
Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysisShyam Sankaran, Greg Gamble, Mark Bolland, et al.The Lancet. Diabetes & Endocrinology|April 8, 2014
The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysisMark J Bolland, Andrew Grey, Greg D Gamble, et al.BMJ (Clinical Research Ed.)|October 1, 2015
Calcium intake and bone mineral density: systematic review and meta-analysisVicky Tai, William Leung, Andrew Grey, et al.The Journal of Clinical Endocrinology and Metabolism|November 11, 2011
Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trialAndrew Grey, Mark Bolland, Sumwai Wong, et al.The Journal of Clinical Endocrinology and Metabolism|February 5, 2020
Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized TrialAndrew Grey, Anne Horne, Greg Gamble, et al.The New Zealand Medical Journal|February 14, 2012
Should measurement of vitamin D and treatment of vitamin D insufficiency be routine in New Zealand?Mark J Bolland, Andrew Grey, James S Davidson, et al.BMJ (Clinical Research Ed.)|April 21, 2011
Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysisMark J Bolland, Andrew Grey, Alison Avenell, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 26, 2010
Prolonged antiresorptive activity of zoledronate: a randomized, controlled trialAndrew Grey, Mark Bolland, Diana Wattie, et al.Endocrinology|November 26, 2002
The phospholipids sphingosine-1-phosphate and lysophosphatidic acid prevent apoptosis in osteoblastic cells via a signaling pathway involving G(i) proteins and phosphatidylinositol-3 kinaseAndrew Grey, Qi Chen, Karen Callon, et al.Pageof 39